Vimarsana
Biggest News Aggregation in the World

Mapi Pharma Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mapi Pharma Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mapi Pharma Ltd Today - Breaking & Trending Today

The Viatris Inc (VTRS) Company: A Short SWOT Analysis - Vimarsana News

The Viatris Inc (VTRS) Company: A Short SWOT Analysis

Decoding Viatris Inc (VTRS): A Strategic SWOT Insight

Source: yahoo.com
Generic Product News: October 2023 - Vimarsana News

Generic Product News: October 2023

The products include Indomethacin 50 mg suppositories, Fluocinolone Acetonide Oil 0.01%, GA Depot 40 mg, Saxagliptin Tablets, 2.5 mg and 5 mg

Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] - Vimarsana News

Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

$ Free Cash Flow $2,300 - $2,700 ___________ Includes the full year expected performance for the planned divestitures and excludes any potential related costs, such as taxes and transaction costs,...

Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis - Vimarsana News

Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis

FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris' long-standing and...

Viatris beats second-quarter revenue estimates, says divestiture plans on track - Vimarsana News

Viatris beats second-quarter revenue estimates, says divestiture plans on track

Viatris Inc beat Wall Street estimates for second-quarter revenue on Monday, on the strength of its branded drug portfolio, sending its shares up 2% in premarket trading. The drugmaker...